CoChat
Sign Up
Cited by 41Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

Jimeno, Antonio, Gupta, Shilpa, Sullivan, Ryan, Do, Khanh T., Akerley, Wallace L., Wang, Ding, Teoh, Deanna, Schalper, Kurt +11 more·2020·Cancer Research
DOI 10.1158/1538-7445.am2020-ct032
Open this paper in CoChat — free account

Abstract

Background: While PD-1/L1 blockade is an effective therapeutic approach for many patients with solid and hematologic malignancies, it is not sufficient to induce tumor regressions in the majority of patients. Optimal T cell responses require T cell receptor activation and co-stimulation, which can be provided via ligation of tumor necrosis factor receptor family members, such as OX40. Binding of OX40 by OX40L in the presence of a recognized antigen promotes CD4+ and CD8+ T cell expansion, enhances memory responses and inhibits regulatory T cell function. mRNA-2416 is a novel mRNA-based lipid nanoparticle therapeutic agent that expresses the wild type human OX40L. Preclinical in vivo anti-tumor activity of a murine mRNA-2416 surrogate and synergy with anti-PD-L1 antibodies in syngeneic cancer models are observed (unpublished). Here we present the findings of a first-in-human study of mRNA-2416 monotherapy delivered intratumorally in solid tumor patients with accessible lesions. Methods: This study tested the safety and efficacy of mRNA-2416 administered every 2 weeks for up to 12 doses in a standard 3+3 phase 1 dose escalation in patients with locally advanced, recurrent or metastatic solid malignancy or lymphoma. Tumor biopsies were collected pre- and post-treatment and evaluated by quantitative immunofluorescence (QIF) and RNA sequencing to characterize OX40L expression and immune response following treatment. Results: As of November 13, 2019, 39 patients have been treated at 4 dose levels from 1-8 mg. mRNA-2416 was generally well-tolerated with no DLTs. 6 out of 39 patients experienced grade 3 treatment related AEs. Out of 14 patients with best overall response of stable disease by RECIST, 6 had stable disease for ≥ 14 weeks, and 4 had tumor shrinkage in the injected lesions. Analyses of paired biopsies from injected lesions by QIF showed increased OX40L protein expression as well as elevated T cell scores post-treatment. Activation of a pro-inflammatory gene expression response post-treatment was observed in many cases, including increased cytolytic activity scores, elevated PD-L1 expression, and stimulation of a T cell-inflamed gene expression profile predictive of anti-PD-1/L1 response. These findings were observed in patients with long duration on study or tumor shrinkage. Conclusion: Intratumoral mRNA-2416 is tolerable at all dose levels studied when given as monotherapy and analyses of tumor post-treatment demonstrate increased OX40L protein expression, elevated PD-L1 levels and pro-inflammatory activity. Taken together with the observation of preclinical in vivo synergy with PD-L1 blockade, these data support the evaluation of a combination of intratumoral mRNA-2416 with the anti-PD-L1 inhibitor durvalumab in solid tumors, which is ongoing in part B of this study. Citation Format: Antonio Jimeno, Shilpa Gupta, Ryan Sullivan, Khanh T. Do, Wallace L. Akerley, Ding Wang, Deanna Teoh, Kurt Schalper, Sima J. Zacharek, Jing Sun, Andressa S. Laino, Joshua Frederick, Honghong Zhou, William Randolph, Stephanie Pascarella, Lisa Johansen, Pamela S. Cohen, ROBERT S. MEEHAN, Todd M. Bauer. A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT032.

Integrity signals

Registry

Crossref · 10.1158/1538-7445.am2020-ct032

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • mRNA-2416, a lipid nanoparticle encapsulating mRNA encoding human OX40L, is in clinical evaluation for the treatment of patients with solid tumours.

    “For example, mRNA-2416, a lipid nanoparticle encapsulating mRNA encoding human OX40L (a ligand of OX40), is in clinical evaluation for the treatment of patients with solid tumours (NCT03323398)214.”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [214]

  • A pro-inflammatory tumour microenvironment can be induced by lipid nanoparticle-mRNA formulations delivering cytokines or co-stimulatory molecules.

    “Alternatively to vaccination, a pro-inflammatory tumour microenvironment can be induced by lipid nanoparticle–mRNA formulations delivering cytokines or co-stimulatory molecules33,106,161,163,214 (Table 2).”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [214]

  • mRNA-2416 was generally well tolerated at different dose levels.

    “mRNA-2416 was generally well tolerated at different does levels214.”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [214]

  • The injected lesions showed an increase in OX40L expression and enhanced T cell activation after mRNA-2416.

    “Moreover, the injected lesions showed an increase in OX40L expression and enhanced T cell activation214.”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [214]

Cited by

Sorted by citations

Related

Authors
Jimeno, A., Gupta, S., Sullivan, R., Do, K. T., Akerley, W. L., Wang, D., Teoh, D., Schalper, K., Zacharek, S. J., Sun, J., Laino, A. S., Frederick, J., Zhou, H., Randolph, W., Pascarella, S., Johansen, L., Cohen, P. S., MEEHAN, R. S., & Bauer, T. M.
Affiliations
  • University of Colorado Cancer Center (US)
  • Cleveland Clinic (US)
  • Massachusetts General Hospital (US)
  • Dana-Farber Cancer Institute (US)
  • University of Utah (US)
  • Henry Ford Hospital (US)
  • University of Minnesota Medical Center (US)
  • Yale University (US)
  • 9MODERNA Tx INC., CAMBRIDGE, MA;
  • Sarah Cannon (US)
ORCID
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2020-08-15
Volume
80
Issue
16_Supplement
Pages
CT032-CT032
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
DOI
10.1158/1538-7445.am2020-ct032
OpenAlex
W3083291045
Cited by
41
References
0
Citations by year
2026: 2 · 2025: 6 · 2024: 8 · 2023: 4 · 2022: 12 · 2021: 7 · 2020: 2
Type
conference abstract
Language
en
Open access
closed
Locations
Cancer Research (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
OX40L, lipid nanoparticle mRNA vaccine, intratumoral injection, durvalumab, PD-L1 blockade, combination immunotherapy, solid tumors, lymphoma, T cell costimulation, tumor-infiltrating lymphocytes, quantitative immunofluorescence, gene expression profiling, first-in-human safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review